4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03278665|
Recruitment Status : Completed
First Posted : September 12, 2017
Last Update Posted : February 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Phase Ib/II open-label, multi-center study with a priming cycle of 4SC-202 to evaluate the safety, tolerability and preliminary efficacy of combination treatment with 4SC-202 and Pembrolizumab. A dose expansion cohort at the Recommended Phase Two Dose (RPTD) will be added.
Adult patients with advanced (unresectable or metastatic) cutaneous melanoma primary refractory or non-responding to anti-PD-1 therapy as most current systemic anti-cancer therapy and for whom no standard therapy is available, will be enrolled. The last administration of anti-PD-1 therapy must have been performed within 6 months prior to screening.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Melanoma||Drug: 4SC-202 in combination with Pembrolizumab||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy|
|Actual Study Start Date :||September 25, 2017|
|Actual Primary Completion Date :||February 2, 2022|
|Actual Study Completion Date :||February 2, 2022|
Experimental: 4SC-202 + Pembrolizumab
Single arm study of 4SC-202 in combination with Pembrolizumab
Drug: 4SC-202 in combination with Pembrolizumab
4SC-202 in combination with Pembrolizumab
- Incidence of Adverse Events [Safety and Tolerability] [ Time Frame: Up to 114 weeks ]Safety and tolerability of the combination of 4SC-202 and Pembrolizumab will be assessed from adverse events.
- Objective Response Rate (ORR) [ Time Frame: Up to 102 weeks ]The Objective Response Rate (ORR) will be defined as the percentage of patients who have achieved a confirmed response of at least Immune-related Complete Response (irCR) or Immune-related Partial Response (irPR)
- Best Overall Response (BOR) [ Time Frame: Up to 102 weeks ]The Best Overall Response defined as the best among all confirmed overall responses (irCR is better than irPR is better than irSD)
- Disease Control Rate (DCR) [ Time Frame: Up to 102 weeks ]The Disease Control Rate (DCR) will be defined as the percentage of patients who have achieved a confirmed response of at least irCR or irPR or a response of irSD
- Duration of Response (DOR) [ Time Frame: Up to 102 weeks ]Duration of response (DOR) is defined as the time from the first documentation of response to the date of disease progression. Patients who have no documented disease progression at the end of the study or who are lost to follow-up or who receive additional anti-neoplastic therapy after discontinuing 4SC-202 and Pembrolizumab will be censored at the date of their last extent of disease assessment or on the first date of additional therapy, respectively.
- Progression Free Survival (PFS) [ Time Frame: Up to 102 weeks ]The time from first dosing (C1D1) to date of first observed progression or death from any cause (whichever comes first). Patients who have not progressed while on study and have not died while on study will be censored at the last evaluable assessment date.
- Time to Progression (TTP) [ Time Frame: Up to 102 weeks ]The time from first dosing (C1D1) to first date of first observed progression. Patients who have not progressed while on study, have not died while on study or experienced a non-disease- related death will be censored at the last evaluable assessment date.
- Overall Survival (OS) [ Time Frame: Up to 102 weeks ]The Overall Survival (OS) is defined as the time from first dosing (C1D1) to date of death from any cause. Patients who have not died while on study will be censored at the last evaluable assessment date
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Main Inclusion Criteria:
- Patients with unresectable stage III or stage IV cutaneous melanoma, as per American Joint Committee on Cancer (AJCC) (Version 8) staging system (must have been histologically confirmed at least once during course of disease). Patients with metastatic tumor of unknown primary site and histology of melanoma are eligible.
- Patients must be primary refractory or non-responding to anti-PD-1 therapy (either as monotherapy or in combination with Ipilimumab)
- Measurable disease by computer tomography (CT) or Magnetic resonance imaging (MRI) per immune-related response evaluation criteria in solid tumors (irRECIST) 1.1 criteria, with longest diameter for non-nodal lesions ≥ 10 mm and ≥ 15 mm in short axis for nodal lesions
- At least one tumor site (either primary site or metastasis) must be accessible for sequential biopsies and patient must consent to the 2 mandatory biopsies. This requirement is not applicable for continuous dosing schedules and may be waived by the sponsor in other individual cases.
Main Exclusion Criteria:
- Patients who achieved a CR or PR, during or after prior anti-PD-1 mono- or anti-CTLA-4/anti-PD-1 combination therapy
- Patients with symptomatic brain metastases/central nervous system (CNS) involvement
- Patients with inadequate organ function
- Therapy with agents known to prolong the QT interval and increase the risk for Torsades de Pointes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03278665
|Medizinische Hochschule Hannover|
|Klinikum der Universität München|
|Istituto Nazionale Tumori Fondazione "G. Pascale"|
|Principal Investigator:||Dirk Schadendorf, MD||Universitätsklinikum Essen|
|Responsible Party:||4SC AG|
|Other Study ID Numbers:||
|First Posted:||September 12, 2017 Key Record Dates|
|Last Update Posted:||February 4, 2022|
|Last Verified:||February 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action